Getty Images
July 14, 2023 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Geraldine M. Jacobson, MD, MBA, MPH, FASTRO, Chair of the ASTRO Board of Directors, in response to the proposed 2024 Medicare Physician Fee Schedule (MPFS) released today by the Centers for Medicare and Medicaid Services (CMS):
“Another year brings another round of cuts to radiation therapy services for people with cancer under the proposed Medicare fee schedule. ASTRO is disappointed that CMS once again undervalues the impact of radiation oncology and intends to cut reimbursement by an additional 2% in 2024 for this essential cornerstone of cancer care. Medicare spends less on all radiation therapy services than it does on just three top cancer drugs, although radiation is utilized by twice as many beneficiaries. Despite this outsized value, CMS has cut radiation oncology physician fee schedule payments by over 20% in the last decade – more than nearly all other physician specialties.
The ongoing cuts to radiation oncology reimbursement, coupled with broader cuts to Medicare services, threaten to decrease patients' ability to receive vital, high-value cancer care close to home by driving practice consolidation and undermining the viability of smaller practices. These cuts also underscore the need for long-term, overarching reimbursement reform that will ensure patients can access the care they need.
ASTRO, the leading medical society for radiation oncology with 10,000 members who are physicians, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapy, recently introduced Radiation Oncology Case Rates (ROCR), a legislative proposal for radiation oncology payment reform. We look forward to working with our Congressional champions to pass the bipartisan Providing Relief and Stability for Medicare Patients Act of 2023 (H.R. 3674) to mitigate the impact of clinical labor cuts. In addition, we need to advance ROCR to increase patient access to care, improve the quality of cancer treatments, reduce disparities for rural and underserved patients, and lower Medicare and patient costs.”
For more details about ROCR, read an overview from ASTRO’s health policy leadership.
For more information: www.astro.org
RELATED CMS CONTENT:
US Government Issues Final Rules for Surprise Billing
CMS Withdraws Guidance on Surprise Billing, Out-of-Network Payment Disputes
ACR Joins "No Surprises Act" Lawsuit to Protect Patient Care
Major Medical Associations Ask Federal Court for Summary Judgement in No Surprises Lawsuit
Radiation Oncologists Applaud Biden-Harris Administration's Renewed Commitment to Cancer Moonshot
Racial/Ethnic Disparities Persist in Lung Cancer Screening Eligibility
Primary Lung Cancers Detected by LDCT are at Lower Risk of Brain Metastases
Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage
USPSTF Expands Lung Cancer Screening Eligibility Thresholds
Low-dose CT for Lung Cancer Screening: Benefit Outweighs Potential Harm
Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage
September 24, 2026 
